​

IDEAYA Biosciences (IDYA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

IDYA Stock Forecast

IDEAYA Biosciences (IDYA) stock forecast, based on 24 Wall Street analysts, predicts a 12-month average price target of $47.40, with a high of $60.00 and a low of $30.00. This represents a 36.44% increase from the last price of $34.74.

$25 $32 $39 $46 $53 $60 High: $60 Avg: $47.4 Low: $30 Last Closed Price: $34.74

IDYA Stock Rating

IDEAYA Biosciences stock's rating consensus is Buy, based on 24 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 22 Buy (91.67%), 2 Hold (8.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 24 0 2 22 Strong Sell Sell Hold Buy Strong Buy

IDYA Price Target Upside V Benchmarks

TypeNameUpside
StockIDEAYA Biosciences36.44%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1311
Avg Price Target$52.00$52.33$44.73
Last Closing Price$34.74$34.74$34.74
Upside/Downside49.68%50.63%28.76%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 263132--18
Feb, 263142--19
Jan, 263132--18
Dec, 253132--18
Nov, 254132--19
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 18, 2026Wedbush$52.00$30.8468.61%49.68%
Jan 21, 2026RBC Capital$45.00$35.7525.87%29.53%
Jan 06, 2026Gregory RenzaTruist Financial$60.00$34.9471.72%72.71%
Nov 24, 2025Truist Financial$59.00$33.9973.58%69.83%
Oct 21, 2025New Street$30.00$30.51-1.67%-13.64%
Oct 21, 2025RBC Capital$41.00$30.5134.38%18.02%
Sep 17, 2025Guggenheim$50.00$24.44104.58%43.93%
Sep 09, 2025Gregory RenzaRBC Capital$38.00$24.7453.60%9.38%
Sep 08, 2025Matthew BieglerOppenheimer$36.00$23.3953.91%3.63%
Sep 04, 2025lvan TuerkcanJMP Securities$41.00$25.7659.16%18.02%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 19, 2026CitigroupBuyBuyhold
Feb 18, 2026Cantor FitzgeraldOverweightOverweighthold
Feb 18, 2026WedbushOutperformOutperformhold
Jan 21, 2026RBC CapitalOutperformOutperformhold
Dec 12, 2025CitigroupBuyBuyhold
Oct 21, 2025Goldman SachsNeutralNeutralhold
Oct 21, 2025RBC CapitalOutperformOutperformhold
Sep 17, 2025GuggenheimBuyBuyinitialise
Sep 09, 2025RBC CapitalOutperformOutperformhold
Sep 09, 2025Wells FargoOverweightOverweighthold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.41$-1.42$-1.96$-3.36$-1.28---
Avg Forecast$-1.23$-1.43$-1.91$-2.47$-2.72$-2.65$-2.72$-1.17
High Forecast$-0.52$-0.24$-1.73$-2.36$-2.28$-0.84$0.03$-0.19
Low Forecast$-2.59$-3.88$-2.07$-2.56$-3.39$-3.98$-4.21$-3.18
Surprise %14.63%-0.70%2.62%36.03%-52.94%---

Revenue Forecast

$0 $140M $280M $420M $560M $700M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$27.94M$50.93M$23.39M$7.00M$218.71M---
Avg Forecast$33.97M$53.92M$28.28M$4.67M$16.04M$60.89M$91.67M$295.06M
High Forecast$63.01M$124.81M$39.58M$10.80M$37.14M$63.24M$212.21M$683.05M
Low Forecast$18.97M$19.30M$19.52M$1.67M$5.74M$58.55M$32.81M$105.61M
Surprise %-17.74%-5.53%-17.30%50.00%1263.17%---

Net Income Forecast

$-300M $-230M $-160M $-90M $-20M $50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-49.76M$-58.66M$-112.96M$-274.48M$-113.70M---
Avg Forecast$-70.62M$-82.47M$-112.96M$-141.31M$-163.02M$-138.49M$-205.28M$-67.49M
High Forecast$-30.08M$-13.63M$-99.56M$-135.52M$-131.19M$-48.12M$1.99M$-11.15M
Low Forecast$-149.09M$-223.44M$-119.24M$-147.10M$-194.84M$-228.86M$-242.18M$-182.86M
Surprise %-29.53%-28.87%-94.24%-30.25%---

IDYA Forecast FAQ

Is IDEAYA Biosciences stock a buy?

IDEAYA Biosciences stock has a consensus rating of Buy, based on 24 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 22 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that IDEAYA Biosciences is a favorable investment for most analysts.

What is IDEAYA Biosciences's price target?

IDEAYA Biosciences's price target, set by 24 Wall Street analysts, averages $47.4 over the next 12 months. The price target range spans from $30 at the low end to $60 at the high end, suggesting a potential 36.44% change from the previous closing price of $34.74.

How does IDEAYA Biosciences stock forecast compare to its benchmarks?

IDEAYA Biosciences's stock forecast shows a 36.44% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for IDEAYA Biosciences over the past three months?

  • March 2026: 16.67% Strong Buy, 72.22% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 15.79% Strong Buy, 73.68% Buy, 10.53% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 16.67% Strong Buy, 72.22% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.

What is IDEAYA Biosciences’s EPS forecast?

IDEAYA Biosciences's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.65, marking a 107.03% increase from the reported $-1.28 in 2025. Estimates for the following years are $-2.72 in 2027, and $-1.17 in 2028.

What is IDEAYA Biosciences’s revenue forecast?

IDEAYA Biosciences's average annual revenue forecast for its fiscal year ending in December 2026 is $60.89M, reflecting a -72.16% decrease from the reported $218.71M in 2025. The forecast for 2027 is $91.67M, and $295.06M for 2028.

What is IDEAYA Biosciences’s net income forecast?

IDEAYA Biosciences's net income forecast for the fiscal year ending in December 2026 stands at $-138M, representing an 21.81% increase from the reported $-114M in 2025. Projections indicate $-205M in 2027, and $-67.49M in 2028.